FTL 004
Alternative Names: FTL-004Latest Information Update: 03 Nov 2024
Price :
$50 *
At a glance
- Originator Sound Biopharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 25 Sep 2024 Preclinical trials in Multiple myeloma in China (Parenteral), before September 2024 (Sound Biopharmaceuticals pipeline, September 2024)